272 related articles for article (PubMed ID: 28391026)
1. Radiopharmaceuticals in the elderly cancer patient: Practical considerations, with a focus on prostate cancer therapy: A position paper from the International Society of Geriatric Oncology Task Force.
Prior JO; Gillessen S; Wirth M; Dale W; Aapro M; Oyen WJG
Eur J Cancer; 2017 May; 77():127-139. PubMed ID: 28391026
[TBL] [Abstract][Full Text] [Related]
2. Radionuclide Therapy for Bone Metastases: Utility of Scintigraphy and PET Imaging for Treatment Planning.
Ahmadzadehfar H; Essler M; Rahbar K; Afshar-Oromieh A
PET Clin; 2018 Oct; 13(4):491-503. PubMed ID: 30219184
[TBL] [Abstract][Full Text] [Related]
3. Bone-targeting radiopharmaceuticals including radium-223.
Brady D; Parker CC; O'Sullivan JM
Cancer J; 2013; 19(1):71-8. PubMed ID: 23337760
[TBL] [Abstract][Full Text] [Related]
4. Integrating bone targeting radiopharmaceuticals into the management of patients with castrate-resistant prostate cancer with symptomatic bone metastases.
Blacksburg SR; Witten MR; Haas JA
Curr Treat Options Oncol; 2015 Mar; 16(3):325. PubMed ID: 25777571
[TBL] [Abstract][Full Text] [Related]
5. Radionuclide cancer therapy.
Hoefnagel CA
Ann Nucl Med; 1998 Apr; 12(2):61-70. PubMed ID: 9637275
[TBL] [Abstract][Full Text] [Related]
6. Radiation dosimetry for radionuclide therapy in a nonmyeloablative strategy.
DeNardo GL; Siantar CL; DeNardo SJ
Cancer Biother Radiopharm; 2002 Feb; 17(1):107-18. PubMed ID: 11915167
[TBL] [Abstract][Full Text] [Related]
7. Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer.
Rowe SP; Drzezga A; Neumaier B; Dietlein M; Gorin MA; Zalutsky MR; Pomper MG
J Nucl Med; 2016 Oct; 57(Suppl 3):90S-96S. PubMed ID: 27694179
[TBL] [Abstract][Full Text] [Related]
8. Does Choline PET/CT Change the Management of Prostate Cancer Patients With Biochemical Failure?
Goldstein J; Even-Sapir E; Ben-Haim S; Saad A; Spieler B; Davidson T; Berger R; Weiss I; Appel S; Lawrence YR; Symon Z
Am J Clin Oncol; 2017 Jun; 40(3):256-259. PubMed ID: 25319322
[TBL] [Abstract][Full Text] [Related]
9. Complimentary role of FDG-PET imaging and skeletal scintigraphy in the evaluation of patients of prostate carcinoma.
Tiwari BP; Jangra S; Nair N; Tongaonkar HB; Basu S
Indian J Cancer; 2010; 47(4):385-90. PubMed ID: 21131750
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin receptors as targets for nuclear medicine imaging and radionuclide treatment.
Maecke HR; Reubi JC
J Nucl Med; 2011 Jun; 52(6):841-4. PubMed ID: 21571797
[TBL] [Abstract][Full Text] [Related]
11. New radiopharmaceutical agents for the treatment of castration-resistant prostate cancer.
Maffioli L; Florimonte L; Costa DC; Correia Castanheira J; Grana C; Luster M; Bodei L; Chinol M
Q J Nucl Med Mol Imaging; 2015 Dec; 59(4):420-38. PubMed ID: 26222274
[TBL] [Abstract][Full Text] [Related]
12. The role of radioisotopes in radiation oncology.
Park CH
Semin Oncol; 1997 Dec; 24(6):639-54. PubMed ID: 9422261
[TBL] [Abstract][Full Text] [Related]
13. Imaging of Prostate Cancer Using
Castellucci P; Ceci F; Fanti S
PET Clin; 2017 Apr; 12(2):137-143. PubMed ID: 28267448
[TBL] [Abstract][Full Text] [Related]
14. Radionuclides delivery systems for nuclear imaging and radiotherapy of cancer.
Hamoudeh M; Kamleh MA; Diab R; Fessi H
Adv Drug Deliv Rev; 2008 Sep; 60(12):1329-46. PubMed ID: 18562040
[TBL] [Abstract][Full Text] [Related]
15. Positron emission tomography for radiation treatment planning.
Grosu AL; Piert M; Weber WA; Jeremic B; Picchio M; Schratzenstaller U; Zimmermann FB; Schwaiger M; Molls M
Strahlenther Onkol; 2005 Aug; 181(8):483-99. PubMed ID: 16044216
[TBL] [Abstract][Full Text] [Related]
16. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
[TBL] [Abstract][Full Text] [Related]
17. Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer.
Iagaru AH; Mittra E; Colletti PM; Jadvar H
J Nucl Med; 2016 Oct; 57(Suppl 3):19S-24S. PubMed ID: 27694165
[TBL] [Abstract][Full Text] [Related]
18. Radiation Safety and Accidental Radiation Exposures in Nuclear Medicine.
Marengo M; Martin CJ; Rubow S; Sera T; Amador Z; Torres L
Semin Nucl Med; 2022 Mar; 52(2):94-113. PubMed ID: 34916044
[TBL] [Abstract][Full Text] [Related]
19. Anti-cancer radiopharmaceuticals.
Hoefnagel CA
Anticancer Drugs; 1991 Apr; 2(2):107-32. PubMed ID: 1958857
[TBL] [Abstract][Full Text] [Related]
20. The bright future of radionuclides for cancer therapy.
Nijsen JF; Krijger GC; van Het Schip AD
Anticancer Agents Med Chem; 2007 May; 7(3):271-90. PubMed ID: 17504155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
